Cellular medicines developer Mesoblast has resubmitted its BLA for approval of Ryoncil (remestemcel-L) in the treatment of children with SR-aGVHD. Remestemcel-L is being developed for inflammatory diseases in children and adults, including steroid-refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. It was only in March that the Food and Drug Administration decided…
a2 Milk Company grows despite decline in China market The a2 Milk Company, which pioneered the use of a2 proteins in milk as a healthy alternative, has reported positive results for 1H24. Revenue was up 3.7 percent to $812.1 million and EBITDA profit up five percent to $113.2 million despite a double-digit decline in the…
Radiopharmaceutical manufacturer Cyclopharm has announced that Duke University Hospital in the United States has signed the first commercial contract for the use of its Technegas lung imaging system in the United States. Following the approval of Technegas by the United States Food and Drug Administration (USFDA) in September, this agreement signifies a major milestone for…
